Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 2/20 | 0.44 |
| ▸ | SKP1 | P63208 | 2/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 11/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201480 | 0.95 | F10 (0.49) | MAPTMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5202412 | 0.95 | F10 (0.49) | MAPTMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5203154 | 0.94 | MAPT (0.46) | MAPTMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL4860738 | 0.91 | F10 (0.49) | MAPTMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5204811 | 0.90 | TP53 (0.42) | MAPTMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5369020 | 0.90 | MAPT (0.51) | MAPTMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5205339 | 0.89 | F10 (0.55) | F10KCNH2 | |
| SCHEMBL5201912 | 0.86 | F10 (0.48) | MAPTMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5202472 | 0.86 | F10 (0.48) | MAPTMEN1KMT2ATSHRSMN1; SMN2 | |
| SCHEMBL5205847 | 0.86 | F10 (0.51) | F10KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307444-B1 | SUBSTITUTED HETEROCYCLIC AMIDES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| EP-1307444-B1 | SUBSTITUTED HETEROCYCLIC AMIDES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040097491-A1 | Substituted heterocyclic amides | HERRON DAVID KENT (US) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097491-A1 | Substituted heterocyclic amides | F12, F11, F8 | MAPT 4238/4885MEN1 669/4885KMT2A 2303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.